BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 27 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Cell, 2019, 176(6):1447-1460

PubMed: 30799039 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30717477 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105914

PubMed: 31634789 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Vet Microbiol, 2018, 227:61-68

PubMed: 30473353 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(20):11622-11642

PubMed: 28977426 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:169

PubMed: 28529930 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Tissue Eng Part A, 2016, 22(17-18):1075-85

PubMed: 27477105 ( click the link to review the publication )

Front Cell Infect Microbiol, 2016, 6:182

PubMed: 28018864 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Am J Reprod Immunol, 2016, 76(5):348-357

PubMed: 27613665 ( click the link to review the publication )

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420 ( click the link to review the publication )
FEBS J, 2014, 281(17):3816-27

PubMed: 25040165 ( click the link to review the publication )

Virology, 2014, 450-451:182-95

PubMed: 24503081 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	NUK5TW9sT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NI\HTnpKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi56IH7N	MWjTRW5ITVJ?
KRX cells	NYiwVJNMTnWwY4Tpc44h[XO\|YYm=	MnH3O{BucW6\|	NGnXRYVKdmirYnn0bY9vKG:oIGPVUW8ufGGpZ3XkJHVNUzFiKIXub45wf25ib4Lp[4lvMSCtaX7hd4Uh\G:vYXnuJIV5eHKnc4Pl[EBqdiCNUmigZ4VtdHNidYPpcochYzN{UG2t[4FudWFvQWTQJIFv\CCveXXsbY4h[mG\|aXOgdJJwfGWrbjDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB5IH3pcpM>	MUeyOlI4PTZ6MR?=
human NKM-1 cell	NIPU[ZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYm0clA6UW6qaXLpeIlwdiCxZjDoeY1idiCQS12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZzOUSg{txO	NVjlVGh6W0GQR1XS
human P30-OHK cell	NWTXdWxMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHPGfWNKdmirYnn0bY9vKG:oIHj1cYFvKFB\|MD3PTGsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTygTWM2OD1yLkS5OlUh\|ryP	NWLwTnJOW0GQR1XS
human YH-13 cell	NGnuc\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGXkfmVKdmirYnn0bY9vKG:oIHj1cYFvKFmKLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43Ojh6ODFOwG0>	M{D2THNCVkeHUh?=
human LXF-289 cell	NFjNPZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo\vTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvKEmFNUC9NE43PTZ7MzFOwG0>	NEnZWHlUSU6JRWK=
human BE-13 cell	NUDYdIFkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVKyOm9XUW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzB2N{eg{txO	M2m0SHNCVkeHUh?=
human RS4-11 cell	NYLGcIpOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|I2QTRizszN	M{DSdXNCVkeHUh?=
human A3-KAW cell	MnniS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGjFeXRKdmirYnn0bY9vKG:oIHj1cYFvKEF\|LVvBW{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzNyNUWg{txO	NV\QOlNWW0GQR1XS
human PA-1 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVq1OGxrUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45ODR{MjFOwG0>	MojzV2FPT0WU
human ES7 cell	MoDxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1[0emlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64N\|U3PiEQvF2=	NEHJT3lUSU6JRWK=
human ES8 cell	MoO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIDYW2pKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPFQ{OzZizszN	NVjoTmZUW0GQR1XS
human SW982 cell	MnztS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlrMTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPVUyOjRizszN	MkPxV2FPT0WU
human VA-ES-BJ cell	M2PwdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXro[\|l7UW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOUi0Olch\|ryP	M37Bc3NCVkeHUh?=
human 697 cell	NH6yZ3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkPpTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkCxOlI{KM7:TR?=	NGH2T5ZUSU6JRWK=
human MOLT-4 cell	NHHLUmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3PTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA{OjR2IN88US=>	NGTDZYtUSU6JRWK=
human D-283MED cell	NFHMfIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NE[xfmZKdmirYnn0bY9vKG:oIHj1cYFvKERvMkizUWVFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yM{m0PEDPpG1?	NY[3[WtXW0GQR1XS
human ALL-PO cell	NITV[WZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFYxPzNizszN	MoLUV2FPT0WU
human NB14 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1z5OWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFYxQDFizszN	NIrxW5NUSU6JRWK=
human NTERA-S-cl-D1 cell	MkfCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3nRTmlvcGmkaYTpc44hd2ZiaIXtZY4hVlSHUlGtV{1kdC2GMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFc4PzVizszN	Mmj0V2FPT0WU
human BFTC-905 cell	NYjnT4xiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnzwTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODhzMEGg{txO	MWfTRW5ITVJ?
human H4 cell	MmTqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4T1[2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkGwNlAyKM7:TR?=	MWjTRW5ITVJ?
human CHP-212 cell	NVKweGZzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{\wfWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTRyM{eg{txO	NEnsWZlUSU6JRWK=
human A204 cell	NIjnRoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4DOWmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU1PjdizszN	MVnTRW5ITVJ?
human NB69 cell	MmXYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkXKTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xOVg3PSEQvF2=	MVXTRW5ITVJ?
human P12-ICHIKAWA cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWnJcohq[mm2aX;uJI9nKGi3bXHuJHAyOi2LQ1jJT2FYSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMUixO\|Eh\|ryP	NGLPZ3NUSU6JRWK=
human L-363 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnjYTY5pcWKrdHnvckBw\iCqdX3hckBNNTN4MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVgyQTdizszN	NUnHXoRYW0GQR1XS
human ES5 cell	NXiwXG9xT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1Hle2lvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPVM2PCEQvF2=	NFnMNpRUSU6JRWK=
human CAL-51 cell	MlfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXfLZm1vUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ{MUW2JO69VQ>?	NUfoV2xmW0GQR1XS
human NBsusSR cell	M1ztU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkK3TY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDV5ODFOwG0>	NE\mUIxUSU6JRWK=
human HOP-92 cell	Mm\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC17MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlczQTNizszN	NVvhOoh4W0GQR1XS
human DU-4475 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV;yR2Q3UW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK0OUDPxE1?	M4PCPXNCVkeHUh?=
human LB1047-RCC cell	MlLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkjoTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK4NUDPxE1?	M324[XNCVkeHUh?=
human D-566MG cell	M1:4XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUHKcY4{UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5\|MES0PEDPxE1?	NGr3NoZUSU6JRWK=
human A375 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{XwU2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|A5PThizszN	M4\QNnNCVkeHUh?=
human ATN-1 cell	MnjHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mlj4TY5pcWKrdHnvckBw\iCqdX3hckBCXE5vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|cyQDVizszN	NXjUVJBtW0GQR1XS
human M059J cell	NGjHUZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{jSUGlvcGmkaYTpc44hd2ZiaIXtZY4hVTB3OVqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM4PjV{IN88US=>	NWfIXG1FW0GQR1XS
human HSC-3 cell	Ml7sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT60OFIxQCEQvF2=	M4DWRXNCVkeHUh?=
human DOHH-2 cell	M4jsfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3n4TmlvcGmkaYTpc44hd2ZiaIXtZY4hTE:KSD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PThzNDFOwG0>	M1;yPHNCVkeHUh?=
human G-402 cell	MoSxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV\iNXpCUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZ3MkWg{txO	MoDnV2FPT0WU
human LC-2-ad cell	MmfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3TMc2lvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDdzM{Kg{txO	MVzTRW5ITVJ?
human LOXIMVI cell	NHnEdWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGnTR\|dKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjVyNUWyJO69VQ>?	NFvNTo5USU6JRWK=
human DK-MG cell	M2TDUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{LTbGlvcGmkaYTpc44hd2ZiaIXtZY4hTEtvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4Ojl6IN88US=>	MY\TRW5ITVJ?
human HOS cell	NXzndXlkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIO3VotKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVc{ODlizszN	MY\TRW5ITVJ?
human BHT-101 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2TycGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd6N{eg{txO	NEPZWoJUSU6JRWK=
human U-2-OS cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmL5TY5pcWKrdHnvckBw\iCqdX3hckBWNTJvT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU5QDB4IN88US=>	NFXJb3VUSU6JRWK=
human D-423MG cell	NEDFXHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxQDB4IN88US=>	NUHjO4ZvW0GQR1XS
human AN3-CA cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFLRNpBKdmirYnn0bY9vKG:oIHj1cYFvKEGQMz3DRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjN7OUGg{txO	MmH0V2FPT0WU
human TE-11 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYfJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62OVI5KM7:TR?=	MkLZV2FPT0WU
human SK-NEP-1 cell	M17ofWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4rXWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ3M{e2JO69VQ>?	NETJUZNUSU6JRWK=
human MG-63 cell	NV6zbVBbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUfTe2oxUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjh3Nkeg{txO	NFPSTpdUSU6JRWK=
human RH-1 cell	MoHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NE\iPYpKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlcxOjd2IN88US=>	M2Dwc3NCVkeHUh?=
human MDA-MB-157 cell	M4nmb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjdzNke0JO69VQ>?	NFfaOYhUSU6JRWK=
human A427 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGnxWJdKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc{PTh7IN88US=>	NUDFPGlOW0GQR1XS
human ES1 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4nXb2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63OVQ2OSEQvF2=	M1jxdHNCVkeHUh?=
human C32 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnmzTY5pcWKrdHnvckBw\iCqdX3hckBEOzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke2N\|kh\|ryP	NIHDU2JUSU6JRWK=
human LAMA-84 cell	MmrGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYLOU5JiUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55Nki3NkDPxE1?	NHznRZJUSU6JRWK=
human YKG-1 cell	NFnnfVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4fI[WlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc4OTJ2IN88US=>	M4Dj[XNCVkeHUh?=
human NCI-H1048 cell	NFXsdYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEKzd5FKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{i1NFkh\|ryP	MmjtV2FPT0WU
human KS-1 cell	MlL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGtUNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkiyPVgh\|ryP	NUXzWVg4W0GQR1XS
human JVM-3 cell	NIPFS4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFPZ[ohKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjR7MTFOwG0>	NF70WoJUSU6JRWK=
human GI-ME-N cell	MkftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk[0TY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjV\|IN88US=>	NHTD[2JUSU6JRWK=
human GT3TKB cell	NUPxXJFqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnzhTY5pcWKrdHnvckBw\iCqdX3hckBIXDOWS1KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg6PjR{IN88US=>	Mne1V2FPT0WU
human CHL-1 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT65NlM4QSEQvF2=	M1[wSXNCVkeHUh?=
human CHP-134 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1zM{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk1PDZ5IN88US=>	MUTTRW5ITVJ?
human 8-MG-BA cell	NH:0PIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXzxO21TUW6qaXLpeIlwdiCxZjDoeY1idiB6LV3HMWJCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57NUe0OEDPxE1?	M1nSc3NCVkeHUh?=
human HO-1-N-1 cell	NGjvdHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3uTY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTdzMUeg{txO	Mnz4V2FPT0WU
human SW1088 cell	M4Hoc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX3tTXl7UW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl7NkezJO69VQ>?	MULTRW5ITVJ?
human SW48 cell	M2CzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3G5b2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFIxPjdizszN	MX7TRW5ITVJ?
human VM-CUB-1 cell	NGnGeFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXLjWVJYUW6qaXLpeIlwdiCxZjDoeY1idiCYTT3DWWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMESxNVkh\|ryP	NEH6cVlUSU6JRWK=
human COLO-800 cell	M{PnVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NELUd5dKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yNUGzOkDPxE1?	MlriV2FPT0WU
human TI-73 cell	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHW5[JFKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yOTN7OTFOwG0>	M3LQfXNCVkeHUh?=
human HN cell	M4\zbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{\KWmlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyNVk5KM7:TR?=	MoTyV2FPT0WU
human DB cell	M1LWTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF\VPJRKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xNlY{OSEQvF2=	M4fEeHNCVkeHUh?=
human Ca9-22 cell	MnnuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2f1NWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yOjh2NzFOwG0>	MUfTRW5ITVJ?
human A549 cell	NWnwUHdPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M37RN2lvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVM5ODhizszN	M3jN[HNCVkeHUh?=
human KGN cell	NUDWXmptT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYDFdYtKUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIzPTl3IN88US=>	M3THcHNCVkeHUh?=
human BCPAP cell	NFjzTGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoTrTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlMyPThizszN	NEHRd\|BUSU6JRWK=
human Ramos-2G6-4C10 cell	NHXqNVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHJidW:\|LULHOk01SzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yN\|c2QSEQvF2=	MkHmV2FPT0WU
human OVCAR-5 cell	MnPjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVvJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI4PzN2IN88US=>	NVTFUZlWW0GQR1XS
human KG-1 cell	MmLLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NI[0UnJKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI4Pzl{IN88US=>	MV;TRW5ITVJ?
human CAKI-1 cell	Moi0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{\s[2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQDB3ODFOwG0>	Mmq1V2FPT0WU
human QIMR-WIL cell	NHTJT41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQDd2NDFOwG0>	NYm3[Y5GW0GQR1XS
human SW1710 cell	M3TOWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnzwTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI6OTR{IN88US=>	MnrzV2FPT0WU
human SK-UT-1 cell	M4rxOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4C0[WlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjl\|M{mg{txO	Ml:1V2FPT0WU
human IST-SL1 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH;TSodKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjN{MUe0JO69VQ>?	NEDtR4FUSU6JRWK=
human SW962 cell	NUfX[nhET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mo\LTY5pcWKrdHnvckBw\iCqdX3hckBUXzl4MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|M4PTdizszN	NEDtT3VUSU6JRWK=
human EM-2 cell	NVL4N2MzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NW\UUpZ5UW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{PTN\|NzFOwG0>	NGmx[G1USU6JRWK=
human D-263MG cell	M4LWVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXHB[GhDUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK2N21IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5\|OEOyO{DPxE1?	NUPiWYRiW0GQR1XS
human T98G cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUHUeIgyUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDh3NzFOwG0>	NIS0[pNUSU6JRWK=
human CTB-1 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jI[GlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM6PzZzIN88US=>	MYDTRW5ITVJ?
human Hs-578-T cell	NYe2NJFzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnjwTY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDF3OEeg{txO	MlvjV2FPT0WU
human SF126 cell	NIHMR2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2DTPWlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{PjJzIN88US=>	MX3TRW5ITVJ?
human NCI-H460 cell	NIG4VWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41Ozl3NTFOwG0>	MlHVV2FPT0WU
human NCI-H1755 cell	M4H6NGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1naPGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53NEC0N{DPxE1?	M4OyRXNCVkeHUh?=
human HL-60 cell	MmnUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWjENnV6UW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTRzNUmg{txO	NWrTd5FGW0GQR1XS
human G-401 cell	NY[1TXJ7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4XiPGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU3ODl7IN88US=>	NVPqTmpFW0GQR1XS
human AGS cell	NFi2UYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1LmeWlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlI2PyEQvF2=	M1\2[XNCVkeHUh?=
human HuO9 cell	M3fVWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHv0eVNKdmirYnn0bY9vKG:oIHj1cYFvKEi3T{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU3PDV4IN88US=>	MUXTRW5ITVJ?
human MFE-280 cell	NXTFWldIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXL5Xoc3UW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53Nk[4OkDPxE1?	MULTRW5ITVJ?
human NCI-H292 cell	NFm1eWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoLHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTd5MkKg{txO	MVvTRW5ITVJ?
human HuO-3N1 cell	NWPoPJczT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1yyfWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWRLUPONUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjB\|MEeg{txO	M2DVPHNCVkeHUh?=
human ES3 cell	M4DOU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVUOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNkKyPFUh\|ryP	NV3MeJZ{W0GQR1XS
human LB2241-RCC cell	NVXyVmpIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHXQ[mRKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5NFc6KM7:TR?=	NEnzeI5USU6JRWK=
human NCI-H1155 cell	NHzFNndIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{PiRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUSwOUDPxE1?	MojKV2FPT0WU
human SW872 cell	M1TxUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj63NFY4PiEQvF2=	NFLDToZUSU6JRWK=
human MHH-ES-1 cell	NVXKfolqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlS5TY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzJ4M{Og{txO	MXTTRW5ITVJ?
human KYSE-150 cell	NUW1e4E1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MojCTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzJ7NzFOwG0>	NX3HclZvW0GQR1XS
human MC-IXC cell	NEHxSGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn3oTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg6PTNizszN	NU\vSI54W0GQR1XS
human HCC1187 cell	NYnXRmNtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhESzFzOEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg6Pjd5IN88US=>	M{Hw[XNCVkeHUh?=
human UMC-11 cell	MnLkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHVOSy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVA1PzdizszN	NH3ZRYRUSU6JRWK=
human NB5 cell	M2Pnfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\q[mxzUW6qaXLpeIlwdiCxZjDoeY1idiCQQkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlk{PzF3IN88US=>	NETMVI5USU6JRWK=
human A2058 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUnnWoFTUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTd6NESg{txO	NWTjOlg2W0GQR1XS
human Becker cell	NXjvbJRyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFvtWHJKdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODFzMUKg{txO	NV34SoVuW0GQR1XS
human CAS-1 cell	M4W5UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGNCWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6wNVU3QSEQvF2=	M372N3NCVkeHUh?=
human SW780 cell	M160PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFv1[nRKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPTZyOTFOwG0>	M3:3RXNCVkeHUh?=
human KM12 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1yzOGlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuN\|AyOzJizszN	NFrXRWVUSU6JRWK=
human PC-3 cell	MmXES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkD6TY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xO\|QyOSEQvF2=	M2rIRnNCVkeHUh?=
human A253 cell	M4f6SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnn1TY5pcWKrdHnvckBw\iCqdX3hckBCOjV\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xPFg6OyEQvF2=	MVHTRW5ITVJ?
human NB10 cell	NXfFNnBIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHzqNIpKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlIzPzd\|IN88US=>	Mne1V2FPT0WU
human A172 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NET2OWFKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ1PTdizszN	NEjGO4hUSU6JRWK=
human A498 cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW2N\|g{KM7:TR?=	MY\TRW5ITVJ?
human SW1573 cell	MoCyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUHwcFVLUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G1O\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjlyNEmxJO69VQ>?	Mkf6V2FPT0WU
human 5637 cell	NXHYd4RbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVvVR3lIUW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPzlyNDFOwG0>	MUjTRW5ITVJ?
human A388 cell	NV2yWFFbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{PPV2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKxMlE{QThizszN	NHXBNXNUSU6JRWK=
human U251 cell	MoDnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGLIOXBKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE4yOTd3IN88US=>	NI\ERXhUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-p38 / p38 / p-JNK / JNK / gD-2 ; PubMed: 28112176 Acta Pharmacol Sin BX-795 inhibition on HSV replication attenuated by overexpression of p38/JNK. HeLa cells with or without JNK1 or p38 overexpression were infected with HSV-2 and total cellular protein was prepared for WB analysis. gD-2, the phosphorylation level of p38 MA䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘 pTBK1 / TBK1 / pPLK1 / PLK1; PubMed: 26772203 Mol Cancer Ther TBK1 mediated activation of the mitotic kinase PLK1. SW210.5 cells were treated with indicated TBK1 inhibitors for 1 hour and then exposed to 50 ng/mL of nocodazole for 18 hours. Western blot detected the signaling change using indicated antibodies, and β䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	28112176 26772203
Growth inhibition assay	Cell viability ; PubMed: 26772203 Mol Cancer Ther Four SCLC cell lines with no MYC amplification were treated with TBK1 inhibitor BX-795 at the titration concentration. Cell viability was performed by CellTiter Glo 4 days after treatment. The growth curve was constructed by GraphPad Prism 6.	26772203

Protocol

Kinase Assay:^[1]	- Collapse Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	- Collapse Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

- Collapse

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

- Collapse

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 27 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 27 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)